Its portfolio includes single-use devices, such as resection and retrieval devices, needles, graspers, and infection control kits, and it also has a strong position in pathology services and imaging technologies. Boston Scientific agreed to pay $8.00 per share, or $208.4 million, for EndoChoice, which works out to 2.8x revenue. This is Boston Scientific's second acquisition this year, following its July 27 th purchase of Cosman Medical Inc. for an undisclosed amount. Cosman develops and distributes radiofrequency (RF) pain management and neurosurgery products. Stryker Corporation (NYSE: SYK) holds the record for the sector's busiest buyer this year, with eight acquisitions. Medtronic (NYSE: MDT) has announced five deals, and Cantel Medical Corp. (NYSE: CMN) and Zimmer Biomet (NYSE: ZBH) are tied with three deals each for the year. We'll see what the fourth quarter brings.